CRISPR-on-Chip for Point-of-Care Diagnostics

TL;DR

This paper reviews CRISPR-on-chip technology for portable, accurate diagnostics, highlighting its potential and challenges in real-world applications.

Contribution

The paper provides a comprehensive review of recent advancements in CRISPR-on-chip diagnostics and outlines future directions.

Findings

CRISPR-on-chip platforms enable portable, real-time detection of biomolecules with high sensitivity.

Integration with microfluidics improves scalability and reduces reliance on complex lab setups.

The study identifies gaps in understanding CRISPR-on-chip integration for point-of-care use.

Abstract

CRISPR-based diagnostic platforms have gained significant
momentum
in recent years, enabling highly sensitive and specific detection
of pathogens and diseases. Due to their practical benefits, these
platforms have become widely adopted in point-of-care (PoC) applications.
CRISPR-on-chip technology integrates CRISPR-Cas platforms with diverse
microfluidic systems, allowing scalability and portable, real-time,
and precise biomolecule detection. This approach enhances diagnostic
accuracy, reduces processing times, and minimizes the need for complex
laboratory infrastructures, unlike in conventional diagnostics. Using
CRISPR-Cas enzymes in microfluidic systems, CRISPR-on-chip platforms
offer key advantages such as single-molecule sensitivity, multiplex
detection, and applicability. However, integration with microfluidics
for PoC applications is still poorly understood, despite CRISPR-Cas
being widely used. This study reviews recent developments in CRISPR-on-chip-based
diagnostics and highlights its potential applications in infectious
diseases, biosensors, and personalized medicine. Furthermore, challenges
and future perspectives in achieving an ideal diagnostic solution
are discussed.

Figures